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The recent article by Mohammed et al. demonstrates an impressive effect of ivermectin mass drug administration
for lymphatic filariasis on the burden of scabies. Partnering scabies research within the evaluation and monitoring
of Neglected Tropical Disease programmes could potentially increase our understanding of the epidemiology and
control of scabies and its important bacterial complications.
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the December 21st issue of Parasites & Vectors [1].
The authors assessed the impact of an annual ivermec-
tin mass drug administration (MDA) programme for
lymphatic filariasis (LF) in Zanzibar, Tanzania, on the
burden of scabies, using what they term a “rapid assess-
ment” methodology. This involved retrospective review
of health clinic records for the number of patients diag-
nosed and treated for scabies. The study observed a re-
duction of 68-98% in scabies cases over a five year
period, indicating that annual MDA with ivermectin
appears to have a significant effect on the burden of sca-
bies in the community. Importantly, the reduction was
also observed in children aged less than 5 years, who
were not included in the ivermectin programme.
Whilst the study did not aim to show causation, the
data represent some of the best available evidence dem-
onstrating the effects of MDA programmes on other
neglected tropical diseases (NTDs), and are the first in-
dication of the potential impact on scabies. Understand-
ing these additional effects is extremely important for
the optimal design of integrated NTD control strategies,
yet they have been overlooked in programmes to date.
Scabies is frequently complicated by bacterial skin in-
fection (impetigo) which, in turn, can lead to a number* Correspondence: Andrew.Steer@rch.org.au
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reproduction in any medium, provided the orof disease processes that carry significant morbidity, in-
cluding severe soft tissue infections, invasive streptococ-
cal and staphylococcal disease, acute post-streptococcal
glomerulonephritis and possibly rheumatic heart disease
[2]. Global efforts toward the control of scabies are
particularly important to reduce the underappreciated
morbidity and mortality of these secondary bacterial
complications. Initial data suggest that MDA with iver-
mectin can not only reduce scabies prevalence, but re-
duce the burden of bacterial skin infection and indirect
markers of renal damage (haematuria) [3].
There is a very large potential for increasing our un-
derstanding of the epidemiology and control of scabies
through a research partnership, linking scabies with
existing NTD control programmes. A number of simple
measures introduced, as part of NTD monitoring and
MDA evaluation, could provide invaluable information
on the impact of ivermectin MDA on scabies and bac-
terial complications.
Whilst we applaud the authors for the publication of
the rapid assessment method as an alternative to tests
for parasite detection, a more direct evaluation of scabies
prevalence would provide a better understanding of the
effect of ivermectin MDA on disease burden. This could
involve an annual cross-sectional prevalence study for
scabies and impetigo in sentinel areas receiving ivermec-
tin MDA. The International Alliance for the Control of
Scabies (IACS) is working toward development and val-
idation of protocols and case definitions for the diagno-
sis of scabies and impetigo, which are needed for bothral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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samples would be required to examine the effect of
ivermectin MDA on scabies complications such as in-
vasive bacterial infection, renal and cardiac disease, but
these are all feasible given the scope of current MDA
programmes; for example the LF programme treated
more than 500 million people in 2011 [4].
As now well established in the London Declaration
[5], through creative collaborations outside of traditional
disease-focussed programmes, comprehensive preven-
tion and control strategies can yield increased benefits
across a range of health outcomes for the most disad-
vantaged global populations.
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